Hadassah

Hadassah Medical Organization’s Heart Imaging Tracer Advances to First-in-Human Trials with $4M EU Grant

Thursday, Feb 18 2016

MEDIA INQUIRES CONTACT:
Renee Young, National Public Relations
ryoung@hadassah.org
(212) 303- 8140

FOR IMMEDIATE RELEASE

European Union Grant Reaffirms Hadassah's Worldwide Leadership in Heart Research in February during American Heart Month

January 18, 2016 NEW YORK — Jerusalem-based Hadassah Medical Organization's (HMO) innovative radioactive heart imaging tracer project, which enables cardiologists to noninvasively and quantitatively view specific changes of blood flow to the heart, has received a €3.69M ($4M US) grant from the European Union's (EU) Horizon 2020 Program. The grant will enable first-in-human clinical trials (Phase 1) to commence immediately in Jerusalem, announced Ellen Hershkin, National President of Hadassah, The Women's Zionist Organization of America, Inc. (HWZOA).

The innovative radioactive heart imaging tracer, invented and developed by Dr. Eyal Mishani, MD, PhD and HMO's Cyclotron and Radiochemistry Unit team, together with HMO cardiologist Dr. Chaim Dannenberg, MD, PhD, was exclusively licensed in 2013 by Hadasit, HMO's technology transfer company, to the grant applicant Synektik S.A., a leading provider of innovative solutions for Medical Imaging in Europe.

The three year grant for this PET/CT cardiac imaging tracer awarded by EU's Horizon 2020 program is one of only three funded projects from 110 applicants in the health field. Currently, HMO is the only hospital in the world with this imaging agent. The announcement coincides with February Heart Health Month in America and re-affirms HMO's worldwide leadership position in heart research.

This invention heralds a new stage in the diagnosis of cardiovascular disease, the leading cause of death in the world. Currently, millions of diagnostic heart catheterizations are performed each year in the United States; less than 50% reveal heart problems that require further intervention. Thus, the new tracer may decrease unnecessary invasive procedures and costs.

First-in-human trials (Phase 1) will begin at HMO in 2016, the first of its kind in Israel with a PET imaging tracer. HMO has already received the approval of both its Helsinki Ethics Committee and Israel's Ministry of Health to launch the trials.

Hadassah National President Ellen Hershkin states, "One of Hadassah's major focuses is to eradicate heart disease in our lifetime and this is another significant step in HMO's journey to do so."

Prof. Mishani explains: "When this imaging agent is injected into the patient, it accumulates in the heart, enabling the physician to measure blood flow in absolute values and pinpoint the location of problems. With heart disease being the most common cause of death worldwide, the grant is an important recognition by the European Commission for our work in translational medicine, our ability to move from the laboratory to the bedside."

Using quantitative imaging for blood flow to the heart, HMO's new imaging agent will help diagnose coronary artery disease to facilitate more accurate diagnoses and treatment methods. It will also enable doctors to measure the damage caused after a heart attack, and predict the degree of recovery after a heart attack or bypass surgery.

Horizon 2020 is the EU's largest research and innovation program.

For more information on Every Beat Counts, Hadassah's Heart Health Program™, visit http://www.hadassah.org/health-medicine-in-us/heart-health/.

###

Hadassah is the largest Jewish women’s organization in the United States. With 330,000 members, associates and supporters across the country, Hadassah brings Jewish women together to effect change and advocate on criticalissues such as medical care and research, women's empowerment, and the security of Israel. Through the Hadassah Medical Organization's (HMO) two hospitals, the world-renowned trauma center and the leading research facility in Jerusalem, Hadassah supports the delivery of exemplary patient care to over a million people every year. HMO serves without regard to race, religion or nationality and earned a Nobel Peace Prize Nomination in 2005 for building “bridges to peace” through equality in medical treatment. For more information, visit www.hadassah.org.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

Tuesday, Jun 12 2018

Hadassah Ophthalmology Department Research Highlighted by JAMA

Thanking the Hadassah Medical Organization’s researchers for their ”excellent submission” to JAMA Ophthalmology regarding a multi-center international study of the variable effectiveness of treatment for neovascular age-related macular degeneration (nAMD), the editors explained that their article was one of just a few from 12 JAMA on-line journals to be highlighted in The JAMA Network Reader this weekend.

READ MORE ›
alt_text

Monday, Jun 11 2018

Ruth Radiano: Passionate New Director of Nursing at Hadassah Hospital Mount Scopus

Translating her passion and professionalism into action, Ruth Radiano, the new Director of Nursing at Hadassah Hospital Mount Scopus, brings a background of 26 years of nursing at Hadassah.

READ MORE ›
alt_text

Thursday, Jun 7 2018

Former NYC Mayor Giuliani Calls Hadassah Hospital a Blessing

Former New York City Mayor Rudy Giuliani and his partner Dr. Maria Ryan, CEO of Cottage Hospital in Woodsville, New Hampshire visited Hadassah Medical Organization in Jerusalem today to get an update on Hadassah’s management of terror events.

READ MORE ›
alt_text

Thursday, Jun 7 2018

Hadassah Researchers Develop Definitive Biomarker for Cardiac Muscle Death and Link it to Death from Sepsis

Hadassah Medical Organization researchers, in collaboration with colleagues at the Hadassah-Hebrew University School of Medicine, have developed a blood test which definitively detects death of cardiac muscle cells following an acute heart attack and in the case of sepsis.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More